Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for Ischemic Stroke Recurrence in Intracranial Atherosclerosis
NCT06447701Phase 3Not yet recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Oct 2025
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
A Phase 3 trial of tocilizumab in intracranial atherosclerosis (ICAD), ischemic stroke, sponsored by Southern Medical University Zhujiang Hospital. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
intracranial atherosclerosis (ICAD)ischemic stroke
Beyond the preview
Go deeper on NCT06447701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06447701.